Page 60 - Helicobacter pylori and Gastric Cancer: From Tumor microenvironment to Immunotherapy
P. 60

 Key Points
   Gastric adenocarcinoma is a very aggressive cancer with a variable response to neoadjuvant therapy and poor overall prognosis. Although neo-adjuvant chemotherapy or chemoradiation (nCRT), combined with surgery significantly improves survival of patients, novel therapeutic options against these malignancies, especially for patients refractory to standard therapies, are urgently needed.
     Immune checkpoint-directed therapy is revolutionizing is oncological medicine, but its potential in gastric cancer is unclear.
     PD-1-directed therapy (e.g. Nivolumab or Pembrolizumab) is associated with increased survival in gastric cancer patients refractory to other treatments and thus a therapeutic option for this group of patients. Targeting PD-L1 or CTLA4 in gastric cancer remains an unproven strategy.
     In lung cancer patients likely to benefit from targeting PD-1 can be selected by staining cancer material for PD-L1. In gastric cancer, however, PD-L1 staining is not useful for selecting patients and should thus not be used for clinical decision making with respect to PD-1 inhibitors
                                     Chapter 3
Chapter 3
54
58


























































































   58   59   60   61   62